Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

474.50 -4.60 (-0.96%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
57 58 Next >
$100 Invested In Vertex Pharmaceuticals 20 Years Ago Would Be Worth This Much Today
Via Benzinga
2 Hot Stocks to Buy and Hold Until You Retire
A perk of investing in growth stocks is that they have a lot of room to run. 
Via The Motley Fool
MarketBeat Week in Review – 5/15 - 5/19
Investors are battling stagflation as they wait for a recession, and the MarketBeat team continues to help you understand where to find opportunities 
Via MarketBeat
Topics Economy Electric Vehicles
Exposures Economy Electric Vehicles Interest Rates
2 Stocks Near 52-Week Highs That Still Look Like Bargains
These stocks are way up but forward-looking expectations still aren't very high. 
Via The Motley Fool
Looking Into Vertex Pharmaceuticals's Recent Short Interest
Via Benzinga
Is CRISPR Therapeutics Stock a Buy Now?
The clinical-stage biotech company has been on the rise. 
Via The Motley Fool
3 Growth Stocks to Buy and Hold
These three stocks defied the bear market last year. 
Via The Motley Fool
$100 Invested In This Stock 10 Years Ago Would Be Worth $500 Today
Via Benzinga
2 Healthcare Stocks You Can Buy and Hold for the Next Decade
These two solid companies should be buoyed by recent tailwinds. 
Via The Motley Fool
3 Biotech Stocks That Are Revolutionizing Healthcare in 2023
Here are three of the best biotech stocks to buy; each is on the verge of significant breakthroughs that may send the price higher. 
Via InvestorPlace
Vertex Pharmaceuticals Hits Record High on Strong Q1 Earnings
Vertex Pharmaceuticals hits record high on strong earnings, FDA approval for cystic fibrosis medication for infants. Analysts recently boosted price targets. 
Via MarketBeat
Exposures Product Safety
2 Stocks You'll Be Glad You Bought at These Prices
Bear markets create opportunities to buy high-growth stocks at discounted valuations. 
Via The Motley Fool
2 Soaring Growth Stocks That Could Rocket Even Higher
One of these stocks is up 57% this year, and the other one has more than tripled already. 
Via The Motley Fool
2 Potentially Explosive Stocks to Buy in May
These companies should outpace the overall market for years. 
Via The Motley Fool
7 Reasons to Buy Vertex Pharmaceuticals Stock Now
It's not too late to invest in this top biotech stock. 
Via The Motley Fool
Analyst Expectations for Vertex Pharmaceuticals's Future
Via Benzinga
Where to Invest $10,000 in a Bear Market
Cautious and aggressive investors both might find opportunities in a bear market. 
Via The Motley Fool
AI-Run ETF Dumps Apple In Favor Of This Chip Stock And Hints At New Opportunity Brewing In Market
Via Benzinga
3 Healthcare Stocks to Buy and Hold for the Next 10 Years
These stocks may help your portfolio thrive over time. 
Via The Motley Fool
This FDA Nod Is a Game Changer for Patients: Could It Equal Billions for Vertex Pharmaceuticals?
Vertex already has generated billions of dollars in earnings from its cystic fibrosis portfolio. 
Via The Motley Fool
2 Cathie Wood Stocks That Can Get You Through Any Recession
Shares of both companies moved higher even as the stock market fell last year. 
Via The Motley Fool
Why CRISPR Therapeutics Stock Is on Fire Today
Thanks to the gene-editing pioneer having a pipeline chock-full of deep value and a possible regulatory approval on tap, investors are bidding up shares today. 
Via The Motley Fool
This Incredible Growth Stock Has All the Hallmarks of a Prototypical Warren Buffett Stock
Vertex Pharmaceuticals faces limited competition in its core area of expertise, has a top-shelf CEO, and is building out a profoundly valuable pipeline of next-generation assets. 
Via The Motley Fool
Market Rally Finishes Strong; Regional Banks, Fed Rate Hike, Jobs Report, Apple In Focus: Weekly Review
The major indexes retreated for most of the week on banking fears, 
Via Investor's Business Daily
1 Incredibly Undervalued Growth Stock to Buy Hand Over Fist in May
This market-beating biotech stock still has more room to run. 
Via The Motley Fool
3 Top Healthcare Stocks to Buy in May
You'll want to hold onto these innovative companies for the long term. 
Via The Motley Fool
Vertex Announces U.S. FDA Approval for KALYDECO® (ivacaftor) to Treat Eligible Infants With CF Ages 1 Month and Older
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Inhibrx Stock Showing Improving Market Leadership; Earns 86 RS Rating
On Wednesday, Inhibrx stock now clears that desired 80-plus Relative Strength threshold, with a jump from 80 to 86 Wednesday. 
Via Investor's Business Daily
Here's 1 Magnificent Reason to Buy Vertex Pharmaceuticals Stock
The bull case for the cystic fibrosis treatment maker is as strong as ever. 
Via The Motley Fool
Vertex Pharmaceuticals, Transocean, And 'One Of The Best Companies' In Staples: CNBC's 'Final Trades'
On CNBC’s “Halftime Report Final Trades,” Jim Lebenthal of Cerity Partners chose Transocean Ltd (NYSE: RIG), after the company reported 
Via Benzinga
< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
57 58 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.